INDICATED FOR THE TREATMENT OF CHRONIC HEPATITIS B IN PATIENTS 12 YEARS OF AGE AND OLDER WITH EVIDENCE OF ACTIVE VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE.
THIS INDICATION IS BASED ON HISTOLOGICAL, VIROLOGICAL, BIOCHEMICAL, AND SEROLOGICAL RESPONSES IN ADULT PATIENTS WITH HBEAG+ AND HBEAG- CHRONIC HEPATITIS B WITH COMPENSATED LIVER FUNCTION, AND WITH CLINICAL EVIDENCE OF LAMIVUDINE-RESISTANT HEPATITIS B VIRUS WITH EITHER COMPENSATED OR DECOMPENSATED LIVER FUNCTION.
ADULT OVER 18 YRS, 10 MG OD.
RESISTANCE TO ADEFOVIR DIPIVOXIL CAN RESULT IN VIRAL LOAD REBOUND WHICH MAY RESULT IN EXACERBATION OF HEPATITIS B AND, IN THE SETTING OF DIMINISHED HEPATIC FUNCTION, LEAD TO LIVER DECOMPENSATION AND POSSIBLE FATAL OUTCOME.
IN ORDER TO REDUCE THE RISK OF RESISTANCE IN PATIENTS WITH LAMIVUDINE RESISTANT HBV, ADEFOVIR DIPIVOXIL SHOULD BE USED IN COMBINATION WITH LAMIVUDINE AND NOT AS ADEFOVIR DIPIVOXIL MONOTHERAPY